Quick Summary
- Lipoprotein(a) is an LDL-like particle with an extra apolipoprotein(a) tail. Its concentration is roughly 80 to 90 percent genetically determined and stays broadly stable across adult life.
- It is causally associated with atherosclerotic cardiovascular disease and with calcific aortic valve stenosis in Mendelian randomisation and large cohort data.
- Roughly one in five people worldwide carry an elevated level, and almost none of them know, because a standard lipid panel does not measure it.
- Diet, training and statins do not meaningfully lower it. Statins may raise it slightly, which does not negate their benefit.
- Targeted RNA-based therapies have produced very large reductions in trials, but cardiovascular outcome results are what will determine whether lowering it changes events.
Most cardiovascular risk factors are things you did. Lipoprotein(a) is something you were dealt. It is the closest thing in preventive cardiology to a genetic verdict, it affects roughly a fifth of the population, and the overwhelming majority of people carrying a high level have never had it measured because it does not appear on the panel their physician ordered.
What Lipoprotein(a) Is
Structurally, Lp(a) is an LDL particle with an additional protein, apolipoprotein(a), covalently bound to its ApoB component by a disulphide bridge. Apolipoprotein(a) is encoded by the LPA gene and bears a striking resemblance to plasminogen, the precursor of the enzyme that dissolves clots. That resemblance is not cosmetic. It gives Lp(a) a plausible route to interfere with fibrinolysis, layering a prothrombotic mechanism on top of the atherogenic one it inherits from its LDL-like core.
The gene contains a variable number of repeated kringle IV type 2 domains, and the number of repeats is inversely related to plasma concentration. Fewer repeats produce a smaller isoform that is secreted more efficiently and circulates at higher concentration. Because repeat number is inherited, so is your Lp(a). This is why the measurement behaves so differently from every other lipid marker: it is essentially a lifelong trait rather than a modifiable state, and one measurement in adulthood usually tells you what you need to know.
The Evidence for Causality
Observational association is weak evidence on its own. What elevates Lp(a) above the crowded field of candidate risk markers is that the genetic evidence supports causation. Variants in LPA that raise lifetime Lp(a) concentration are associated with higher rates of myocardial infarction and calcific aortic valve disease, and because those variants are allocated at conception they are not confounded by diet, smoking, or socioeconomic status in the way observational exposure is.
Willeit and colleagues analysed baseline and on-statin Lp(a) across statin outcome trials and found that elevated Lp(a) predicted cardiovascular events both before and during statin treatment, meaning the risk it carries is not abolished by lowering LDL cholesterol. Nordestgaard and colleagues have summarised the accumulated evidence in recent reviews, and the European Atherosclerosis Society consensus process concluded that measurement should be far more widespread than it currently is. Elevated Lp(a) has also been linked to kidney disease in Mendelian randomisation work, suggesting the vascular consequences extend beyond the coronary and valvular disease that dominated early research.
The aortic valve association is worth separating out, because it is a distinct disease process. Lp(a) appears to drive valve calcification through a pathway involving oxidised phospholipids carried on the particle. Calcific aortic stenosis has no medical therapy; the treatment is valve replacement. A risk factor that predicts it is therefore worth knowing about early.
Who Should Be Tested, and When
The argument for near-universal one-time measurement is unusually strong. The test is inexpensive, the result is stable for life so it does not need repeating, and a high value changes how aggressively everything else should be managed. Several national guidelines now recommend measuring it at least once in every adult; others restrict it to those with a family history of premature cardiovascular disease, personal early events, or unexplained progression despite good lipid control.
| Group | Why it matters |
|---|---|
| Family history of heart attack or stroke before 55 in men or 65 in women | The single strongest clinical trigger. Lp(a) is a common explanation for unexplained family clustering. |
| Personal cardiovascular event at a young age | Reclassifies residual risk and typically justifies more aggressive ApoB lowering. |
| Known familial hypercholesterolaemia | Lp(a) and FH together produce risk substantially above either alone. |
| Aortic stenosis, or a family history of it | Lp(a) is one of the few identified drivers of valve calcification. |
| Anyone using compounds with adverse cardiovascular effects | Knowing you carry a fixed, unmodifiable risk factor changes the calculus on every optional risk you take on top of it. |
| Everyone else, once | Cheap, one time, and a fifth of people are elevated without knowing. |
One practical note on units. Laboratories report Lp(a) either as mass in mg/dL or as particle concentration in nmol/L, and the two do not convert reliably because particle mass varies with isoform size. Molar reporting in nmol/L is preferred and is what most modern guidance uses. If you compare results across laboratories, check the units before drawing conclusions.
What Actually Lowers It
Very little, which is the frustrating part. Dietary change, aerobic training, weight loss, fish oil, niacin at high dose, and every supplement marketed for the purpose have either no meaningful effect or an effect too small to matter clinically. Statins do not lower it and may raise it marginally, a finding that has been misread in some corners of the internet as a reason to avoid statins. It is not: the ApoB lowering statins deliver outweighs a small Lp(a) rise, and Willeit’s analysis showed statin-treated patients still benefit.
PCSK9 inhibitors lower Lp(a) by roughly 20 to 30 percent as a side effect of their main mechanism, and lipoprotein apheresis lowers it substantially but is invasive, expensive, and reserved for extreme cases. The therapies designed specifically for the target are RNA-based. Antisense oligonucleotides and small interfering RNA agents directed at LPA messenger RNA have produced reductions of 80 to 90 percent and more in phase 2 work. O’Donoghue and colleagues reported large, durable lowering with olpasiran in patients with established cardiovascular disease, with extension data showing effects persisting well beyond the dosing interval.
The essential caveat: none of these agents has yet demonstrated that lowering Lp(a) reduces cardiovascular events. Lipid research is full of interventions that moved a biomarker impressively and delivered nothing clinically. Cardiovascular outcome trials for these agents are running, and until they read out, the honest position is that we have a causal risk factor and a set of drugs that lower it convincingly, and we do not yet have proof that the combination translates into fewer heart attacks.
What to Do With a High Result
Since the factor itself is currently not modifiable outside of trials, a high value is best used as an amplifier on everything else. It is a reason to be more aggressive about ApoB lowering, more attentive to blood pressure, more serious about not smoking, and a strong argument for imaging with a coronary artery calcium score to see whether disease is already present. It is also a reason to tell your siblings and children, because it is inherited and their result is likely to resemble yours.
Under the Tony Huge Laws of Biochemistry Physics, this falls under governors versus accelerators, with an uncomfortable twist. Lp(a) is a governor you cannot currently release. What you can do is stop stacking optional accelerators of risk on top of a load you did not choose. Somebody with a high Lp(a) who is also running compounds that suppress HDL, raise ApoB and raise blood pressure is compounding a fixed disadvantage with a set of variable ones. Knowing the number is what makes that trade-off visible instead of invisible.
Where This Fits in the Bigger Picture
Monitoring is the part of enhancement that nobody posts about, and it is the part that decides how long you get to keep doing this. Testing gives you a feedback loop; without one you are guessing with your organs. Start with the Enhanced Athlete Protocol bloodwork guide, then work through the full protocol hub to see how testing, training, nutrition and recovery connect. If you are early in this, the beginners page is the right entry point.
Frequently Asked Questions
What is lipoprotein(a)?
Lipoprotein(a) is a cholesterol-carrying particle similar to LDL but with an additional protein called apolipoprotein(a) attached. Its blood concentration is largely determined by variation in the LPA gene, is set early in life, and remains fairly stable thereafter. Elevated levels are associated with atherosclerotic cardiovascular disease and with calcification of the aortic valve.
How often should lipoprotein(a) be tested?
For most people, once is sufficient. Because the level is primarily genetic and stable across adult life, repeat testing rarely adds information unless it is being used to monitor a therapy that specifically targets it. This is unusual among lipid markers, most of which need periodic rechecking.
Can diet or exercise lower lipoprotein(a)?
Not to any meaningful degree. Unlike LDL cholesterol and triglycerides, lipoprotein(a) responds poorly to dietary change, weight loss and aerobic training. Statins do not lower it either. PCSK9 inhibitors reduce it modestly, and RNA-based drugs designed to target it have achieved large reductions in trials, though cardiovascular outcome data for those agents are still pending.
Does high lipoprotein(a) mean I will have a heart attack?
No. It is a risk factor, not a diagnosis, and many people with elevated levels never have an event. It shifts probability rather than determining outcome, and it is most useful as a reason to manage every other modifiable risk factor more aggressively and to consider imaging to see whether disease is actually present.
Who should get tested for lipoprotein(a)?
Anyone with a family history of early cardiovascular disease, a personal event at a young age, familial hypercholesterolaemia, or aortic valve disease has a clear indication. Beyond those groups, an increasing number of guidelines support measuring it once in all adults, given the low cost, the stability of the result, and how many carriers are otherwise unaware.
References
- Nordestgaard BG, Langsted A. “Lipoprotein(a) and cardiovascular disease.” Lancet, 2024. doi:10.1016/S0140-6736(24)01308-4 (PMID 39278229)
- Willeit P, et al. “Baseline and on-statin treatment lipoprotein(a) levels for prediction of cardiovascular events: individual patient-data meta-analysis of statin outcome trials.” Lancet, 2018. doi:10.1016/S0140-6736(18)31652-0 (PMID 30293769)
- Kronenberg F, et al. “Frequent questions and responses on the 2022 lipoprotein(a) consensus statement of the European Atherosclerosis Society.” Atherosclerosis, 2023. doi:10.1016/j.atherosclerosis.2023.04.012 (PMID 37188555)
- O’Donoghue ML, et al. “Small Interfering RNA to Reduce Lipoprotein(a) in Cardiovascular Disease.” N Engl J Med, 2022. doi:10.1056/NEJMoa2211023 (PMID 36342163)
- O’Donoghue ML, et al. “The Off-Treatment Effects of Olpasiran on Lipoprotein(a) Lowering: OCEAN(a)-DOSE Extension Period Results.” J Am Coll Cardiol, 2024. doi:10.1016/j.jacc.2024.05.058 (PMID 39168564)
- Bay Simony S, et al. “High Lipoprotein(a) as a Cause of Kidney Disease: A Population-Based Mendelian Randomization Study.” J Am Coll Cardiol, 2024. doi:10.1016/j.jacc.2024.08.059 (PMID 39387759)